FDA to expedite review of Takeda's ulcerative colitis drug

The FDA granted priority-review status to Takeda Pharmaceutical's application to market vedolizumab for the treatment of patients with moderately to severely active ulcerative colitis. The designation will shorten the drug review period from one year to eight months.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ